DigestRedComo funciona
Red
/
Empresas
Nu
No verificado

Numab Therapeutics AG

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

6 Comunicados de prensa

Ver todos los comunicados de prensa
18/12/2025
Biotecnología
Medicina Salud Bienestar
Anuncios breves
Numab Therapeutics Achieves Milestone in Second Collaboration Project with Boehringer Ingelheim
Fuente
Numab Therapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
13/11/2025
Biotecnología
Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for Multispecific Antibody NM81 in Inflammatory Bowel Disease (IBD)
Fuente
Numab Therapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
25/09/2025
Biotecnología
Medicina Salud Bienestar
Gestión empresarial/Administración de Empresas
Numab Therapeutics Achieves Milestone in Collaboration with Boehringer Ingelheim
Fuente
Numab Therapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
09/09/2025
Biotecnología
Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer
Fuente
Numab Therapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
09/01/2025
Biotecnología
Finanzas
Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
Fuente
Numab Therapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
30/10/2024
Biotecnología
Medicina Salud Bienestar
Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors
Fuente
Numab Therapeutics AG
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0